Newsletter Tool

Today's Rundown

Groundbreaking antitrust trial over DaVita's alleged hiring practices could set new precedent
High-flying Pfizer may disappoint on Comirnaty and Paxlovid sales in Q1, analyst warns
AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target
Fitbit tails Apple Watch with FDA-cleared algorithm to passively check for afib
AACR: Bristol Myers details Opdivo's presurgery lung cancer win, with an early sign of survival benefit
AACR: BioNTech showcases post-Comirnaty future with early cancer vaccine efficacy data
Payers cheer CMS decision on Aduhelm as push to lower Part B premiums picks up steam
PerkinElmer to lay off 75 amid termination of California COVID testing contract
Stryker lays off 88 workers, plowing ahead with plan to close Florida facility and eliminate 495 jobs
FDA's Califf on accelerated approval: 'In God, we trust, everyone else must bring good evidence'
Pfizer signals big M&A plans with new CFO Denton, the money manager behind the CVS-Aetna merger
Insomnia drug maker Idorsia amps up awareness push with eye-opening Alliance for Sleep survey
UnitedHealth makes $100M investment in affordable housing
Pfizer to drop $74M for COVID cough-screening smartphone app developer

Featured Story

Groundbreaking antitrust trial over DaVita's alleged hiring practices could set new precedent

By Heather Landi

The Department of Justice charges that DaVita and its former CEO schemed to block top employees and managers at the company from getting recruited by competitors through non-solicitation deals and other restrictions. The closely watched criminal conspiracy trial could have far-reaching implications for how businesses hire talent from one another.

High-flying Pfizer may disappoint on Comirnaty and Paxlovid sales in Q1, analyst warns

By Fraiser Kansteiner

Pfizer’s BioNTech-partnered COVID-19 vaccine Comirnaty and its antiviral pill Paxlovid are destined to reap many billions in 2022, but the company’s first-quarter pandemic haul may come in lighter than previously thought, one group of analysts predicts.

AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target

By Annalee Armstrong,Angus Liu

Finding a way to drug KRAS-mutated cancers was a major leap forward for oncology, and we have Amgen to thank for getting the first therapy across the finish line. But Novartis, for one, sees room for improvement.

Fitbit tails Apple Watch with FDA-cleared algorithm to passively check for afib

By Andrea Park

Fitbit's PPG technology is designed to work in the background throughout the day and night when a wearer is still or asleep.

AACR: Bristol Myers details Opdivo's presurgery lung cancer win, with an early sign of survival benefit

By Angus Liu

Bristol Myers Squibb presented details on what triggered a quick FDA nod in March for Opdivo in early-stage non-small cell lung cancer before surgery, including a disease worsening benefit across patient groups and an early sign of life extension.

AACR: BioNTech showcases post-Comirnaty future with early cancer vaccine efficacy data

By Annalee Armstrong

BioNTech’s post-Comirnaty future is emerging, with early phase 1/2 data from a solid tumor CAR-T cell therapy showing evidence of efficacy and a safety profile deemed manageable by the famed German biotech.

Payers cheer CMS decision on Aduhelm as push to lower Part B premiums picks up steam

By Robert King

Payers cheered CMS' decision to finalize narrow Medicare coverage for Biogen's controversial Alzheimer's drug Aduhelm, and some stakeholders want a quick decision on lowering Part B premiums.

PerkinElmer to lay off 75 amid termination of California COVID testing contract

By Andrea Park

The cuts are linked to a $1.7 billion contract PerkinElmer signed with California’s Department of Public Health in August 2020 to provide COVID-19 lab testing and reporting services for the state.

Stryker lays off 88 workers, plowing ahead with plan to close Florida facility and eliminate 495 jobs

By Andrea Park

The next wave in a yearslong program of rolling layoffs at a Stryker facility in Florida is scheduled to take place at the end of May, the company said in a recent filing with the state.

FDA's Califf on accelerated approval: 'In God, we trust, everyone else must bring good evidence'

By Max Bayer

In an exclusive interview with Fierce Biotech, FDA Commissioner Robert Califf says the agency needs to do a better job of getting post-market data as it looks to fortify trust in the accelerated approval program. His comments came hours before the Centers for Medicare and Medicaid Services stuck with its coverage decision for Biogen's treatment for Alzheimer's.

Pfizer signals big M&A plans with new CFO Denton, the money manager behind the CVS-Aetna merger

By Angus Liu

Pfizer has signed on a new chief financial officer whose dealmaking experience could prove invaluable for the New York pharma as it looks to deploy its COVID-19 vaccine and drug windfall.

Insomnia drug maker Idorsia amps up awareness push with eye-opening Alliance for Sleep survey

By Ben Adams

Idorsia created the Alliance for Sleep just a few months ago, but they've hit the ground running, publishing a new survey with eye-opening insights about insomnia. It's part of Idorsia's awareness-raising to support its Quviviq launch—a push that also features actress Jennifer Aniston.

UnitedHealth makes $100M investment in affordable housing

By Paige Minemyer

UnitedHealth Group has invested an additional $100 million in affordable housing initiatives.

Pfizer to drop $74M for COVID cough-screening smartphone app developer

By Conor Hale

The Australia-based ResApp Health uses machine learning to analyze a person’s coughs to help diagnose a range of respiratory diseases.

PM Tracker

Featured Story

Groundbreaking antitrust trial over DaVita's alleged hiring practices could set new precedent

Top Stories

High-flying Pfizer may disappoint on Comirnaty and Paxlovid sales in Q1, analyst warns

AACR: Novartis hops on KRAS craze with early data, seeking to improve on undruggable target

Fitbit tails Apple Watch with FDA-cleared algorithm to passively check for afib

AACR: Bristol Myers details Opdivo's presurgery lung cancer win, with an early sign of survival benefit

AACR: BioNTech showcases post-Comirnaty future with early cancer vaccine efficacy data

Payers cheer CMS decision on Aduhelm as push to lower Part B premiums picks up steam

PerkinElmer to lay off 75 amid termination of California COVID testing contract

Stryker lays off 88 workers, plowing ahead with plan to close Florida facility and eliminate 495 jobs

FDA's Califf on accelerated approval: 'In God, we trust, everyone else must bring good evidence'

Pfizer signals big M&A plans with new CFO Denton, the money manager behind the CVS-Aetna merger

Insomnia drug maker Idorsia amps up awareness push with eye-opening Alliance for Sleep survey

UnitedHealth makes $100M investment in affordable housing

Pfizer to drop $74M for COVID cough-screening smartphone app developer